Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.44 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22311946 | 1.00 | FOLH1 (0.44) | FOLH1GLP1RDGAT1 | |
| SCHEMBL22311640 | 1.00 | FOLH1 (0.44) | FOLH1GLP1RDGAT1 | |
| SCHEMBL22311947 | 1.00 | FOLH1 (0.44) | FOLH1GLP1RDGAT1 | |
| SCHEMBL15919185 | 1.00 | FOLH1 (0.44) | FOLH1GLP1RDGAT1 | |
| SCHEMBL22134370 | 0.92 | GLP1R (0.42) | FOLH1GLP1R | |
| SCHEMBL23077727 | 0.91 | GLP1R (0.49) | FOLH1GLP1R | |
| SCHEMBL17287165 | 0.91 | GLP1R (0.49) | FOLH1GLP1R | |
| SCHEMBL15919171 | 0.91 | GLP1R (0.49) | FOLH1GLP1R | |
| SCHEMBL22311645 | 0.90 | GLP1R (0.38) | FOLH1GLP1R | |
| SCHEMBL22311639 | 0.90 | GLP1R (0.38) | FOLH1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4108675-A1 | PREPARATION AND USE OF IMMUNOSTIMULATORY COUPLING COMPLEX WHICH IS DELIVERED AND ACTIVATED IN TARGETED MANNER | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-11319341-B2 | Immune-stimulating soluble doxorubicin-conjugated complex | YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-16 | — | — | US | disclosed |
| US-20200247842-A1 | Immune-stimulating soluble doxorubicin-conjugated complex | YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO LTD (CN) | 2020-08-06 | — | — | US | disclosed |
| EP-2949665-B1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | NPPA, NPR1, NPR3 | FOLH1 2196/4885GLP1R 15/4885DGAT1 2348/4885 |
| US-20200247842-A1 | Immune-stimulating soluble doxorubicin-conjugated complex | TLR3, CD40, TLR6 | FOLH1 2230/4885GLP1R 4535/4885DGAT1 2209/4885 |
| US-11319341-B2 | Immune-stimulating soluble doxorubicin-conjugated complex | TLR3, CD40, TLR6 | FOLH1 2230/4885GLP1R 4535/4885DGAT1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.